Advanced search
Publication Cover
Journal of Dermatological Treatment Volume 33, 2022 - Issue 1
Submit an article Journal homepage
2,017
Views
1
CrossRef citations to date
0
Altmetric
Articles

A subset analysis of efficacy and safety outcomes from phase 3 clinical studies of ixekizumab for the treatment of patients with severe plaque psoriasis

Lynda Spelmana Veracity Clinical Research, Brisbane, AustraliaView further author information
,
Diana Rubelb Woden Dermatology, ACT, AustraliaView further author information
,
Alan Brnabicc Eli Lilly Australia Pty Limited, West Ryde, AustraliaView further author information
,
Nicole Burkhardtc Eli Lilly Australia Pty Limited, West Ryde, AustraliaView further author information
,
Elisabeth Riedld Eli Lilly Ges.m.b.H, Vienna, Austria;e Department of Dermatology, Medical University of Vienna, Vienna, AustriaView further author information
&
Peter Foleyf Skin Health Institute, Carlton, Australia;g The University of Melbourne, St Vincent's Hospital Melbourne, Fitzroy, AustraliaCorrespondence[email protected]
View further author information
Pages 329-335 | Received 16 Mar 2020, Accepted 01 Apr 2020, Published online: 21 Apr 2020

Reprints and Permissions

Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.

To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.

Order Reprints Request Permissions

For more information please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.